Changes in Lipid Indices in HIV+ Cases on HAART

We assess long-term changes in lipid levels in human immunodeficiency disease- (HIV-) infected patients undergoing highly active antiretroviral treatment (HAART) and their association with diabetes mellitus (DM) and thyroid dysfunction. We observed changes in the levels of total cholesterol (TC) and total triglyceride (TG) of 63 HIV-infected patients in the 6 years from starting HAART and analyzed correlations between relevant parameters. TC levels of patients with normal baseline TC levels as well as those diagnosed with DM or impaired fasting glucose (IFG) increased significantly ($P < 0.05$) as did the TG levels of patients with normal baseline TG levels ($P < 0.05$). TC levels of patients with hypercholesterolemia in the year HAART was initiated were significantly higher than those of patients with normal baseline TC levels ($P < 0.05$) for all 6 years. TC levels of patients diagnosed with DM were significantly higher than those with euglycemia ($P < 0.05$) 2 and 4 years after HAART commencement. Levels of TC, high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) were correlated negatively with viral load, whereas levels of TC and very-low-density lipoprotein-cholesterol (VLDL-C) were correlated positively with CD4+ cell counts before HAART commencement. Linear mixed-effect model demonstrated disturbance of glucose metabolism and HAART containing nevirapine and CD4+ cell count were positively correlated with TC levels after HAART commencement. These findings suggest that there are changes in the lipid levels of patients undergoing HAART, with the potential risk of dyslipidemia.

1. Introduction

Acquired immune deficiency syndrome (AIDS) has been considered to be a chronic disease necessitating long-term management rather than an acute fatal disease that requires highly active antiretroviral therapy (HAART). Patients infected with the human immunodeficiency virus (HIV) can survive for long periods, so non-AIDS diseases account primarily for the disease burden of this patient population.

Dyslipidemia is highly prevalent among HIV-infected patients and may contribute to an increased risk of atherosclerosis as well as cardiovascular disease (CVD), which is one of the main causes of death in this population [1–3]. Consequently, management of lipid levels is an important aspect of the care of HIV-infected patients.

The characteristics of dyslipidemia associated with HAART include decreased levels of high-density lipoprotein-cholesterol (HDL-C) and increased levels of low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) [4]. HAART can be associated with an increase in insulin resistance [5]. Riddler et al. claimed that significant reductions in serum levels of TC, HDL-C, and LDL-C are seen after HIV infection. However, levels of TC and LDL-C increased notably after HAART initiation but mean levels of HDL-C remained below baseline levels throughout follow-up [6]. Choe et al. evaluated 66 HIV-infected patients and reported that patients diagnosed with hypertriglyceridemia and hypercholesterolemia accounted for 12.3% and 5.8% of cases, respectively [7]. Also, we have shown that serum lipid levels of patients with hyperglycemia are higher than those of patients with euglycemia [8].
Endocrine dysfunction (e.g., thyroid dysfunction) is common in HIV-infected patients [9]. Thyroid hormone has an essential role in lipid metabolism [10]. Several studies have demonstrated that thyroid dysfunction is more common in HIV-infected patients and hypothyroidism is the most common one [11]. Hypothyroidism can lead to increases in TC levels as well as reduction of lipolysis and gluconeogenesis. Patients with severe hyperthyroidism have a higher insulin clearance rate, which gives rise to hyperglycemia [12].

Previously, we undertook cross-sectional studies that did not detail dynamic changes over several years. Consequently, we decided to carry out a longitudinal retrospective study to further observe variations in lipid indices. We hypothesized that the lipid levels of HIV-infected patients undergoing HAART would increase with time and that lipid levels would correlate with glucose metabolism and the levels of thyroid hormones.

2. Materials and Methods

2.1. Ethical Approval of the Study Protocol. All procedures undertaken in studies involving human participants were in accordance with the ethical standards set by Ruhr University Bochum (Bochum, Germany) and/or national research committees and with the Declaration of Helsinki. Written informed consent is not required for this type of study.

2.2. Patients. Data for 188 HIV-infected patients undergoing HAART at Saint Josef Hospital, Ruhr University Bochum, from 2000 to 2017, were collected. The final study population was 63 patients.

Patient age, sex, route of transmission, HAART, and the date of diagnosis and the date HAART started were recorded. Levels of TC, triglyceride (TG), glucose, HDL-C, LDL-C, very-low-density lipoprotein-cholesterol (VLDL-C), LDL-C:HDL-C ratio, cluster of differentiation (CD)4+ cell count, and viral load (VL) in the year HAART was started, as well as 2, 4, and 6 years after HAART was started, were collected.

2.3. Criteria. Inclusion criteria were patients: (i) diagnosed with HIV infection and undergoing HAART; (ii) aged >18 years; (iii) continuing HAART.

Exclusion criteria were patients (i) with acute HIV infection; (ii) with severe, life-threatening complications; (iii) who were pregnant; (iv) with autoimmune diseases; (v) with data of TC or TG which is incomplete.

2.4. Normal Ranges of Lipid Indices Tested. The normal ranges of the indices analyzed were TC, <200 mg/dL; TG, <150 mg/dL; glucose, 74–106 mg/dL; HDL-C, 33–84 mg/dL; LDL-C, 69–149 mg/dL; LDL-C:HDL-C ratio, 2.5–3.5; thyroid-stimulating hormone (TSH), 0.35–4.94 μIU/mL; free triiodothyronine (FT3), 1.71–3.71 pg/mL; free thyroxine (FT4), 0.70–1.48 ng/dL; CD4+ cells, 300–1400/μL; activated CD8+ human leukocyte antigen D-related (HLA-DR)+ T cells, 300–200/μL.

2.5. Definitions. “Euglycemia” was defined as a glucose level within normal range. “Impaired fasting glucose” (IFG) was denoted as a glucose level of 101–125 mg/dL recorded at least twice. “Diabetes mellitus” (DM) represented a glucose level >125 mg/dL [13]. “Hypothyroidism” referred to a low FT3 level and/or FT4 level with/without a high TSH level. “Hyperthyroidism” was defined as a high FT3 level and/or FT4 level with/without a low TSH level. “Subclinical hypothyroidism” denoted a high TSH level with normal levels of FT3 and FT4. “Subclinical hypothyroidism” represented a low TSH level with normal levels of FT3 and FT4.

2.6. Laboratory Tests. VL was determined using a standard reverse transcription-polymerase chain reaction system (COBAS® Amplipcr HIV-1 Monitor Test, v1.5; Roche Diagnostic Systems, Branchburg, NJ, USA) with a lower limit of detection of 50 HIV-1 RNA copies/mL. The number of CD4+ cells and activated CD8+ HLA-DR+ T cells was measured by flow cytometry (FACACanto™ II; Becton Dickinson, Franklin Lakes, NJ, USA). Serum levels of TC, TG, HDL-C, LDL-C, and VLDL-C were determined by an automatic biochemical analyzer (AU5800; Beckman Coulter, Brea, CA, USA).

2.7. Statistical Analyses. Data analyses were undertaken using SPSS v20 (IBM, Armonk, NY, USA). Numeric variables were expressed as the mean ± standard deviation and qualitative variables as the number of cases (percentages). Repeated-measure tests were used to evaluate trends in lipid levels, after which Student's t-test or one-way ANOVA followed by a post hoc test was carried out to analyze differences between and among groups. The Pearson correlation coefficient was used to assess the association between data of normal distribution and Spearman correlation coefficient to nondistribution data. Linear mixed-effects model considering sex, diagnosis of glycometabolism, age, taking nevirapine, or not as fixed effects, and lgVL and CD4+ cell counts as random effects was made to assess the correlation between some essential data and TC levels. P < 0.05 (two-tailed) was considered significant.

3. Results

3.1. Clinical Information. Table 1 showed basic clinical information of patients before HAART commencement. Of the 63 patients enrolled, 82.5% were male. The mean age of the study cohort was 40.47 ± 9.40 years. Forty-two patients were infected with HIV after male homosexual sex, 16 after heterosexual sex, and five by an unknown route. Thirty-five patients received two nucleoside reverse transcriptase inhibitor (NRTIs) plus one nonnucleoside reverse transcriptase inhibitor (NNRTIs). Duration of diagnosis before HAART commencement is 2.43 ± 3.79 years. The baseline TC levels of 50 patients were normal and 13 were higher than the upper limit of normal. Based on the levels of thyroid hormones, 11 patients were diagnosed as having hypothyroidism, five with subclinical hypothyroidism, and two with hyperthyroidism. According to glucose levels, 14
Patients were divided into two groups according to their baseline TC level. Fifty patients had a baseline TC level within normal range (normal group) and 13 had a baseline TC level higher than the upper limit of normal (hypercholesterolemia group).

There were significant changes in the TC levels of the two groups with increasing time ($P < 0.05$) and the TC levels of the hypercholesterolemia group were significantly higher than those of the normal group ($P < 0.05$) over the whole 6 years (ESM Table 1a). In addition, the TC level (in mg/dL) of the hypercholesterolemia group was significantly higher than that of the normal group for each year (225.77 ± 27.59 vs. 162.84 ± 36.15; 239.38 ± 43.38 vs. 195.06 ± 45.29; 238.00 ± 33.09 vs. 202.18 ± 50.38; 229.46 ± 37.81 vs. 201.22 ± 41.08; $P < 0.05$) (ESM Table 1a, Figure 1(a)). For the normal group, changes in TC levels over the 6 years were significant ($P < 0.05$) and TC levels 2, 4, and 6 years after HAART commencement were remarkably higher than that of the year in which HAART was started. Over the same period, the TC levels of the hypercholesterolemia group did not exhibit a significant difference ($P > 0.05$).

Similarly, we grouped patients according to their glucose metabolism. The TC levels of patients with different glucose metabolism changed significantly over time ($P < 0.05$) (ESM Table 2, Figure 1(c)) and there were significant differences among the DM, IFG, and euglycemia groups ($P < 0.05$). The TC levels (in mg/dL) of the DM group were significantly higher than those of the euglycemia group 2 and 4 years after HAART commencement ($P < 0.05$). However, the TC levels of the IFG and DM groups 2, 4, and 6 years after HAART commencement were significantly higher than those in the year HAART was started ($P < 0.05$). Also, the TC levels of IFG and DM groups increased significantly from the year HAART started to the fourth year ($P < 0.05$) and decreased in the sixth year, but nonsignificantly ($P > 0.05$).

TC levels did not show a significant difference in groups with different thyroid function ($P > 0.05$).

### 3.3. Changes in TG Levels

Patients were divided into two groups according to their baseline TG level. Forty-one

### Table 1: Clinical information for 63 patients before HAART commencement.

| Variables                          | Mean (±SD) or number (%) |
|------------------------------------|--------------------------|
| Age (years)                        | 40.47 ± 9.40             |
| Sex                                |                          |
| Male                               | 52 (82.5%)               |
| Female                             | 11 (17.5%)               |
| HIV transmission category          |                          |
| Male homosexual                    | 42 (66.7%)               |
| Heterosexual                       | 16 (25.4%)               |
| Unknown                            | 5 (7.9%)                 |
| HAART regimen                      |                          |
| 2 NRTI + PI                        | 14 (22.2%)               |
| 2 NRTI + NNRTI                     | 35 (55.6%)               |
| 2 NRTI + II                        | 3 (4.8%)                 |
| Other                              | 11 (17.5%)               |
| Duration of diagnosis (years)      | 2.43 ± 3.79              |
| Baseline TC level                  |                          |
| Normal                             | 50 (79.4%)               |
| Increased                          | 13 (20.6%)               |
| Baseline TG level                  |                          |
| Normal                             | 41 (65.1%)               |
| Increased                          | 22 (34.9%)               |
| Thyroid function                   |                          |
| Normal                             | 45 (71.4%)               |
| Abnormal                           | 18 (28.6%)               |
| Sub-hypothyroidism                 | 5 (7.9%)                 |
| Overt hypothyroidism               | 11 (17.5%)               |
| Overt hyperthyroidism              | 2 (3.2%)                 |
| Glucose metabolism                 |                          |
| Euglycemia                         | 15 (23.8%)               |
| IFG                                | 34 (54.0%)               |
| DM                                 | 14 (22.2%)               |
| HBV or HCV co-infection            |                          |
| neither                            | 48 (76.2%)               |
| HBV                                | 13 (20.6%)               |
| HCV                                | 2 (3.2%)                 |

HIV: human immunodeficiency virus; HAART: highly active antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; II: integrase inhibitor; TC: total cholesterol; TG: total triglyceride; IFG: impaired fasting glucose; DM: diabetes mellitus; HBV: hepatitis-B virus; HCV: hepatitis-C virus.

Levels of the hypercholesterolemia group were significantly higher than those of the normal group ($P < 0.05$) over the whole 6 years (ESM Table 1a). In addition, the TC level (in mg/dL) of the hypercholesterolemia group was significantly higher than that of the normal group for each year (225.77 ± 27.59 vs. 162.84 ± 36.15; 239.38 ± 43.38 vs. 195.06 ± 45.29; 238.00 ± 33.09 vs. 202.18 ± 50.38; 229.46 ± 37.81 vs. 201.22 ± 41.08; $P < 0.05$) (ESM Table 1a, Figure 1(a)). For the normal group, changes in TC levels over the 6 years were significant ($P < 0.05$) and TC levels 2, 4, and 6 years after HAART commencement were remarkably higher than that of the year in which HAART was started. Over the same period, the TC levels of the hypercholesterolemia group did not exhibit a significant difference ($P > 0.05$).

| Variables                          | Mean (±SD) or number (%) |
|------------------------------------|--------------------------|
| Age (years)                        | 40.47 ± 9.40             |
| Sex                                |                          |
| Male                               | 52 (82.5%)               |
| Female                             | 11 (17.5%)               |
| HIV transmission category          |                          |
| Male homosexual                    | 42 (66.7%)               |
| Heterosexual                       | 16 (25.4%)               |
| Unknown                            | 5 (7.9%)                 |
| HAART regimen                      |                          |
| 2 NRTI + PI                        | 14 (22.2%)               |
| 2 NRTI + NNRTI                     | 35 (55.6%)               |
| 2 NRTI + II                        | 3 (4.8%)                 |
| Other                              | 11 (17.5%)               |
| Duration of diagnosis (years)      | 2.43 ± 3.79              |
| Baseline TC level                  |                          |
| Normal                             | 50 (79.4%)               |
| Increased                          | 13 (20.6%)               |
| Baseline TG level                  |                          |
| Normal                             | 41 (65.1%)               |
| Increased                          | 22 (34.9%)               |
| Thyroid function                   |                          |
| Normal                             | 45 (71.4%)               |
| Abnormal                           | 18 (28.6%)               |
| Sub-hypothyroidism                 | 5 (7.9%)                 |
| Overt hypothyroidism               | 11 (17.5%)               |
| Overt hyperthyroidism              | 2 (3.2%)                 |
| Glucose metabolism                 |                          |
| Euglycemia                         | 15 (23.8%)               |
| IFG                                | 34 (54.0%)               |
| DM                                 | 14 (22.2%)               |
| HBV or HCV co-infection            |                          |
| neither                            | 48 (76.2%)               |
| HBV                                | 13 (20.6%)               |
| HCV                                | 2 (3.2%)                 |

HIV: human immunodeficiency virus; HAART: highly active antiretroviral treatment; TC: total cholesterol; TG: total triglyceride; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; VL: viral load; VLDL-C: very-low-density lipoprotein-cholesterol; TSH: thyroid-stimulating hormone; FT3: free triiodothyronine.

| Variables | r   | P   |
|-----------|-----|-----|
| TC & TG   | 0.339 | 0.015 |
| TC & HDL-C | 0.456 | 0.019 |
| TC & LDL-C | 0.856 | 0.000 |
| TC & lgVL | -0.511 | 0.000 |
| TC & CD4  | 0.499 | 0.000 |
| TG & VL    | 0.693 | 0.000 |
| HDL-C & lgVL | -0.516 | 0.007 |
| VLDL-C & CD4 | 0.621 | 0.001 |
| LDL-C & TSH | 0.555 | 0.021 |
| LDL-C & lgVL | -0.396 | 0.045 |
| FT3 & CD4  | 0.596 | 0.002 |
| lgVL & CD4 | -0.512 | 0.000 |

HCART: highly active antiretroviral treatment; TC: total cholesterol; TG: total triglyceride; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; VL: viral load; VLDL-C: very-low-density lipoprotein-cholesterol; TSH: thyroid-stimulating hormone; FT3: free triiodothyronine.

Table 2: Correlation between relevant parameters before HAART.
patients had a normal baseline level (normal group) and 22 had a TG level higher than the upper limit of normal (hypertriglyceridemia group).

The TG levels of the hyperglyceridemia group were significantly higher than those of the normal group (P<0.05). The TG levels (in mg/dL) of the hyperglyceridemia group were higher than that of the normal group for each year since HAART commencement (220.27 ± 86.68 vs. 125.73 ± 91.32, P<0.05; 203.95 ± 159.59 vs. 176.80 ± 158.32, P>0.05; 276.91 ± 192.21 vs 167.76 ± 170.96, P<0.05; 239.05 ± 203.49 vs 157.10 ± 144.10, P>0.05) (ESM Table 1b, Figure 1(b)). The TG levels of the normal group changed significantly over the 6 years of HAART (P<0.05).

There were no significant differences among patients with different glucose metabolism and thyroid function (P>0.05).

3.4. Changes in CD4+ Cell Counts. Changes in CD4+ cell counts and activated CD8+ HLA-DR T-cell counts were analyzed to assess therapeutic effects and patient immunity (ESM Table 3, Figure 2).

CD4+ cell counts (per μL) increased significantly over the years (307 ± 185.56 vs. 489.94 ± 200.24 vs. 542.13 ± 215.85 vs. 571.21 ± 230.96, P<0.05). CD4+ cell counts were compared among patients with different thyroid function. There was a significant difference among groups with different thyroid function until 4 years after HAART commencement (P<0.05) and this significance disappeared at 6 years after HAART commencement. The hypothyroidism group had the lowest CD4+ cell count (per μL) over the whole 6 years, and it was significantly lower than that of the euthyroidism group in the year HAART started as well as 2 and 4 years after (181.91 ± 135.79 vs. 315.49 ± 177.97, 352.27 ± 142.25 vs. 504.47 ± 199.76, 387.00 ± 170.44 vs. 567.11 ± 205.39, P<0.05; 461.09 ± 203.43 vs. 586.42 ± 223.93, P>0.05). However, there were no significant differences in groups with different glucose metabolism. The activated CD8+ HLA-DR T-cell counts of patients diagnosed with hypothyroidism were significantly higher (P<0.05) than those of patients diagnosed with euthyroidism or subclinical hypothyroidism in the year HAART started. From 2 years since HAART commencement, the activated CD8+ HLA-DR T-cell counts of patients diagnosed with hyperthyroidism
were significantly higher than those of patients diagnosed with hypothyroidism, euthyroidism, or subclinical hypothyroidism (P < 0.05).

3.5. Correlations between Indices before HAART. Correlations between indices before patients started HAART were done to analyze relationship of HIV infection and TC levels, as HAART may change the pattern of patients’ lipid metabolism and VL levels. Levels of TC, HDL-C, and LDL-C correlated negatively with VL (R₁ = –0.511, R₂ = –0.516, R₃ = –0.396, and P < 0.05) (Table 2). Levels of TC and VLDL-C correlated positively with the CD4+ cell count (R₁ = 0.499, R₂ = 0.621, and P < 0.05). The CD4+ cell count correlated negatively with VL (R = –0.512, P < 0.05). In addition, levels of FT3 and VLDL-C were correlated positively with CD4+ cell count (R₁ = 0.596, R₂ = 0.621, and P < 0.05).

3.6. Factors Associated with TC. The result of linear mixed-effect model was made to explore factors influence TC levels in the six years since patients received HAART (Table 3). The result showed that patients diagnosed as IFG and DM compared with euglycemia (β₁ = 27.84, β₂ = 45.41, and P < 0.05), HAART including nevirapine (β = 24.79, P < 0.05), and CD4+ cell count (β = 0.004, P < 0.05) positively correlated with TC levels in the six years since HAART commencement.

4. Discussion

In general, in the present study, the VL of most patients was below the limit of detection and CD4+ cell counts increased continually after treatment. These observations suggest that a favorable clinical curative effect had been elicited.
Changes in lipid metabolism after HAART were observed in our study. However, the data for the levels of HDL-C, LDL-C, VLDL-C, and LDL-C:HDL-C ratio were incomplete. Hence, changes in the levels of TC and TG over time were analyzed. We found that several patients with baseline levels of TC and TG within normal ranges could suffer hypercholesterolemia or hypertriglyceridemia over 6 years of HAART. The levels of TC and TG of these patients increased remarkably overall. We assumed that physicians monitored the levels of TC and TG upon acceptance of HAART irrespective of whether patients had hypercholesterolemia or hypertriglyceridemia at that time.

The TC levels of patients with hyperglycemia (IFG and DM) also increased significantly in the first 4 years from HAART commencement. The interactions between disturbances in glucose metabolism and lipid metabolism are complicated. One mainstream hypothesis is that insulin resistance can lead to dyslipidemia [14]. We found no significant relationship between levels of TC and glucose before HAART commencement but noted a significant difference among patients with different glucose metabolism as well as positive correlation between pathogenicity (IFG and DM) with TC levels, both implying that a disturbance in glucose metabolism (and not the glucose level) affected TC levels. Thus, we suggest that the insulin resistance of patients with IFG or DM results in an increase in TC levels. Hyperglycemia and hyperlipidemia are risk factors for CVD. Hence, patients with IFG or DM should avoid CVD risk factors as much as possible and physicians should take this into consideration when proposing the HAART regimen. Besides, it is recognized that protease inhibitors are responsible for increases in levels of TC and TG [15].

We observed that the LDL level was correlated positively with the TSH level before HAART commencement, although there were no remarkable differences among patients with different thyroid function. According to Yingyun Gong and his colleagues, TSH elevated concentration of LDL-c by upregulating hepatic PCSK9 expression [16]. However, Goldberg et al. demonstrated that T3 treatment leads to a remarkable reduction in TC levels [17]. Yazbeck and colleagues stated that the TC level of patients with hypothyroidism increased and that treatment with thyroid hormone would help to lower the TC level; they attributed this phenomenon to the higher morbidity of atherosclerosis in patients with hypothyroidism [18]. Al-Tonsi et al. demonstrated that the levels of TC and TG of patients with hypothyroidism increased and that the TC level was correlated significantly with levels of T4 and TSH [19]. Taken together, these data suggest that patients with thyroid dysfunction are more susceptible to dyslipidemia.

We noted significant changes in levels of TC and TG from the year HAART started to 2 years after HAART commencement in patients with normal baseline levels of TC and TG, as well as those diagnosed with IFG or DM. However, there were no significant changes from 2 years of HAART commencement, such as between year 2 and year 4. We suggest that disorders in lipid metabolism occur mainly in the early years after HAART commencement.

Levels of TC, HDL-C, and LDL-C were correlated negatively with VL before HAART commencement in the present study. HIV seroconversion was ascribed to reductions in levels of TC, HDL-C and LDL-C according to Multicenter AIDS Cohort Study [6]. HDL-C facilitates foam cells to excrete cholesterol, has anti-inflammatory and anti-thrombotic effects, protects endothelial cells, and prevents CVD. Hence, eliminating a virus is crucial for CVD prophylaxis. In the present study, TC levels were correlated negatively with VL, which was in accordance with the work of Baker and colleagues [20]. Madeddu and coworkers stated that HIV-infected patients not undergoing HAART suffer hypocholesterolemia [9]. TC levels were correlated negatively with the HIV load before HAART commencement, which could influence the cholesterol excretion of monocytes by downregulating expression of key cholesterol efflux transporter genes such as ABCA1 and ABCG1 in monocytes and affect expression of β-Hydroxy β-methylglutaryl-CoA (the rate-determining enzyme responsible for cholesterol biosynthesis). Suppression of cholesterol excretion reduces TC levels in plasma and promotes the formation of foam cells, which accelerates atherosclerosis development [21]. CD4+ cell count was positively correlated with TC and VLDL levels before HAART commencement. Furthermore, during six years since HAART started, there was still a positive correlation between CD4+ cell count and TC levels. This was in accordance with the findings of Melaku Adal et al [22].

Long-term HAART might result in dyslipidemia. Nevirapine was found to be positively correlated with TC levels in this study while there was no statistical significance between tenofovir and emtricitabine with TC levels. However, Alex Marzel et al. concluded that HAART containing tenofovir was negatively correlated with TC levels [23]. Fasting levels of triglycerides, TC, and LDL-C of patients taking stavudine have been reported to be higher than those for patients taking tenofovir [24].

The main strength of our study was that it was a 6-year follow-up study with complete repeat measurement of the levels of TC and TG as well as HIV viral load. Moreover, with continuous and good compliance, therapeutic effect was satisfactory.

There were three main limitations in our study. First, we found the TC level 6 years after HAART commencement to be lower than that at 4 years, but it increased persistently in the first 4 years from HAART commencement. This phenomenon may have been because the TC level benefited from HIV clearance, an increase in the CD4+ cell count with improvement of disease, and supplementation with thyroid hormones, or it was temporary, in which case the TC level could increase again. Therefore, following up TC levels for a longer time would be a good strategy. Second, the number of patients diagnosed with subclinical hypothyroidism or hyperthyroidism was few. As a result, enlarging the sample size is crucial to increase the reliability of our data. Finally, levels of TSH, FT3, FT4, HDL-C, LDL-C, VLDL-C, and the LDL-C:HDL-C ratio were not detected regularly, so we could not observe changes in these indices.
5. Conclusions

HIV-infected patients tend to suffer from dyslipidemia, especially those with hyperglycemia and thyroid dysfunction. It may be necessary to prophylactically treat this population with antilipidemic medicine as even patients with normal TC are inclined to dyslipidemia.

Data Availability

The SPSS data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors would like to thank the native English speaking scientists of Elixigen Company (Huntington Beach, California) for editing their manuscript. This work was supported by the National Science and Technology Major Project during the 13th Five-Year Plan of China (Grant no.2017ZX10105001-005).

Supplementary Materials

See Table 1a-3 in the Supplementary Material for comprehensive image analysis. (Supplementary Materials)

References

[1] T. Kelesidis and J. S. Currier, "Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection," *Endocrinology and Metabolism Clinics of North America*, vol. 43, no. 3, pp. 665–684, 2014.

[2] J. E. Sackoff, D. B. Hanna, M. R. Pfeiffer, and L. V. Torian, "Causes of death among persons with aids in the era of highly active antiretroviral therapy: New York City," *Annals of Internal Medicine*, vol. 145, no. 6, pp. 397–406, 2006.

[3] C. Grunfeld, J. A. Delaney, C. Wankee et al., "Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study," *AIDS*, vol. 23, no. 14, pp. 1841–1849, 2009.

[4] N. E. O. S. Husain and M. H. Ahmed, "Managing dyslipidemia in HIV/AIDS patients: Challenges and solutions," *HIV/AIDS - Research and Palliative Care*, vol. 7, pp. 1–10, 2015.

[5] A. Carr, K. Samaras, S. Burton et al., "A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors," *AIDS*, vol. 12, no. 7, pp. F51–F58, 1998.

[6] S. A. Riddler, E. Smit, S. R. Cole et al., "Impact of HIV infection and HAART on serum lipids in men," *Journal of the American Medical Association*, vol. 289, no. 22, pp. 2978–2982, 2003.

[7] D. H. Oh, J. Y. Ahn, S. I. Kim et al., "Metabolic complications among Korean patients with HIV infection: The Korea HIV/AIDS cohort study," *Journal of Korean Medical Science*, vol. 32, no. 8, pp. 1268–1274, 2017.

[8] C. Jin, S. Ji, T. Xie et al., "Severe dyslipidemia and immune activation in HIV patients with dysglycemia," *HIV Clinical Trials*, vol. 17, no. 5, pp. 189–196, 2016.

[9] G. Madeddu, A. Spasu, F. Chessa et al., "Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study," *Clinical Endocrinology*, vol. 64, no. 4, pp. 375–383, 2006.

[10] R. Mullur, Y.-Y. Liu, and G. A. Brent, "Thyroid hormone regulation of metabolism," *Physiological Reviews*, vol. 94, no. 2, pp. 355–382, 2014.

[11] S. Ji, C. Jin, S. Hoxtermann et al., "Prevalence and influencing factors of thyroid dysfunction in HIV-infected patients," *BioMed Research International*, vol. 2016, Article ID 3874257, 11 pages, 2016.

[12] J.-P. Randin, L. Tappy, B. Scazzeigia, E. Jequier, and J. P. Felber, "Insulin sensitivity and exogenous insulin clearance in Graves’ disease. Measurement by the glucose clamp technique and continuous indirect calorimetry," *Diabetes*, vol. 35, no. 2, pp. 178–181, 1986.

[13] C. Zhang, F. C. Chow, Y. Han et al., "Multicenter cohort study of diabetes mellitus and impaired fasting glucose in HIV-infected patients in China," *Journal of Acquired Immune Deficiency Syndromes*, vol. 68, no. 3, pp. 298–303, 2015.

[14] G. Shor-Posner, A. Basit, Y. Lu et al., "Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection," *American Journal of Medicine*, vol. 94, no. 5, pp. 515–519, 1993.

[15] D. Périard, A. Telenti, P. Sudre et al., "Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors," *Circulation*, vol. 100, no. 7, pp. 700–705, 1999.

[16] Y. Gong, Y. Ma, Z. Ye et al., "Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression," *Metabolism - Clinical and Experimental*, vol. 76, pp. 32–41, 2017.

[17] I. J. Goldberg, L.-S. Huang, L. A. Huggins et al., "Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway," *Endocrinology*, vol. 153, no. 11, pp. 5143–5149, 2012.

[18] R. Yazbeck, P. Benoit, B. Roche, M. B. Boeglin, and I. Tauveron, "Primary hypothyroidism in the adult older than 60 years. Characteristics and follow-up after initiation of replacement treatment in hospital," *Presse Medicale*, vol. 30, pp. 1193–1198, 2001.

[19] A. A. Al-Tonsi, A. A. Abdel-Gayoum, and M. Saad, "The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disorders," *Experimental and Molecular Pathology*, vol. 76, no. 2, pp. 182–187, 2004.

[20] P. J. Barter, S. Nicholls, K. Rye, G. M. Anantharamiah, M. Navab, and A. M. Fogelman, "Antiinflammatory properties of HDL," *Circulation Research*, vol. 95, no. 8, pp. 764–772, 2004.

[21] A. Maisa, A. C. Hearps, T. A. Angelovich et al., "Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration," *AIDS*, vol. 29, no. 12, pp. 1445–1457, 2015.
[22] M. Adal, R. Howe, D. Kassa, A. Aseffa, and B. Petros, “Associations of gender and serum total cholesterol with CD4+ T cell count and HIV RNA load in antiretroviral-naïve individuals in Addis Ababa,” *BMC Public Health*, vol. 18, no. 1, p. 943, 2018.

[23] A. Marzel, R. D. Kouyos, S. Reinschmidt et al., “Dietary patterns and physical activity correlate with total cholesterol independently of lipid-lowering drugs and antiretroviral therapy in aging people living with human immunodeficiency virus,” *Open Forum Infectious Diseases*, vol. 5, no. 4, Article ID ofy067, 2018.

[24] J. V. R. Madruga, I. Cassetti, J. M. A. H. Suleiman et al., “The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: Three-year follow-up after switching therapy,” *HIV Clinical Trials*, vol. 8, no. 6, pp. 381–390, 2007.